 The prognosis of elderly patients with relapsed or refractory acute myeloid leukemia AML is grave. Because of their chronological age andor the presence of multiple co-morbidities, treatment-related mortality in elderly patients with AML is quite high although higher intensive treatment is mandatory to overcome chemoresistant characteristic of their disease. Several regimens have been evaluated as salvage chemotherapy for relapsed or refractory AML such as MitoxantroneHigh dose Cytarabine or AmsacrineHigh dose Cytarabine. These regimens could achieve complete remission CR in a part of patients, but resulted in higher treatment related mortality TRM. Accordingly, less intensive salvage regimen is needed for elderly patients with relapsed or refractory AML. 